Mylan NV (NASDAQ:MYL) was the recipient of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 11,608,600 shares, a growth of 12.0% from the April 30th total of 10,365,400 shares. Currently, 2.3% of the shares of the stock are sold short. Based on an average trading volume of 7,260,000 shares, the days-to-cover ratio is presently 1.6 days.

A number of equities research analysts recently issued reports on MYL shares. Morgan Stanley set a $32.00 price target on shares of Mylan and gave the company a “buy” rating in a research note on Wednesday, May 8th. BidaskClub raised shares of Mylan from a “strong sell” rating to a “sell” rating in a research note on Tuesday, April 30th. Barclays started coverage on shares of Mylan in a research note on Tuesday, June 11th. They issued an “overweight” rating and a $26.00 price target on the stock. Royal Bank of Canada dropped their price target on shares of Mylan to $26.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 8th. Finally, Credit Suisse Group reissued a “buy” rating and issued a $37.00 price target on shares of Mylan in a research note on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $34.15.

MYL traded up $0.11 on Friday, hitting $18.32. 10,853,321 shares of the company’s stock were exchanged, compared to its average volume of 6,957,151. Mylan has a fifty-two week low of $16.63 and a fifty-two week high of $39.59. The company has a quick ratio of 0.85, a current ratio of 1.51 and a debt-to-equity ratio of 1.20. The stock has a market cap of $9.39 billion, a PE ratio of 4.00, a price-to-earnings-growth ratio of 0.94 and a beta of 1.73.

Mylan (NASDAQ:MYL) last announced its earnings results on Tuesday, May 7th. The company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.03. Mylan had a net margin of 2.14% and a return on equity of 18.96%. The company had revenue of $2.50 billion for the quarter, compared to analysts’ expectations of $2.70 billion. During the same quarter in the previous year, the company posted $0.96 EPS. The firm’s quarterly revenue was down 7.0% on a year-over-year basis. As a group, research analysts anticipate that Mylan will post 4.28 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its holdings in shares of Mylan by 2.6% during the 4th quarter. BlackRock Inc. now owns 39,965,771 shares of the company’s stock worth $1,095,061,000 after acquiring an additional 1,018,811 shares during the period. Vanguard Group Inc raised its holdings in shares of Mylan by 1.4% during the 3rd quarter. Vanguard Group Inc now owns 35,774,112 shares of the company’s stock worth $1,309,333,000 after acquiring an additional 506,649 shares during the period. Pzena Investment Management LLC raised its holdings in shares of Mylan by 0.3% during the 1st quarter. Pzena Investment Management LLC now owns 21,027,676 shares of the company’s stock worth $595,924,000 after acquiring an additional 71,010 shares during the period. Geode Capital Management LLC raised its holdings in shares of Mylan by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 7,875,204 shares of the company’s stock worth $215,460,000 after acquiring an additional 1,026,731 shares during the period. Finally, FIL Ltd raised its holdings in shares of Mylan by 14.1% during the 1st quarter. FIL Ltd now owns 6,468,868 shares of the company’s stock worth $183,327,000 after acquiring an additional 799,051 shares during the period. Institutional investors and hedge funds own 83.71% of the company’s stock.

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Featured Article: How to calculate the annual rate of depreciation

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.